TRDANot HalalF
Unlock full report, free

Compliance Status

Not Halal

Screened on Oct 14, 2026 · AAOIFI Standard 21

F

Non-Compliant

0Score

Is Entrada Therapeutics, Inc. (TRDA) halal? Not Halal. Based on AAOIFI screening, Entrada Therapeutics, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Quote this verdict

HalalScreener rates Entrada Therapeutics, Inc. (TRDA) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Oct 14, 2026. Source: https://halalscreener.app/en/stock/TRDA

Business activity

What the company sells is permissible.

Passed

Company debt

Close to the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

28.4% of 30.0% limit
PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Card needed, nothing charged today

Screened according to AAOIFI Standard 21

What this means for you

Most scholars advise not holding TRDA

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

Entrada Therapeutics, Inc.

TRDA: Is Entrada Therapeutics, Inc. Halal?

Entrada Therapeutics, Inc.

NASDAQHealthcareUS

$4.37

Market Cap: 170.2M

Get an email if TRDA's halal status changes

We re-screen Entrada Therapeutics, Inc. daily. If the verdict moves, you hear about it the same day.

Free. One click sets it up, and you can unsubscribe any time.

About Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.

Sector: Healthcare · Industry: Biotechnology

Why this does not pass

  • Interest-bearing deposits are over the 30% limit.

Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.

Shariah Compliance Status

AAOIFI Standard 21Updated Oct 14, 2026

See which ratio caused the failure.

See the exact debt ratio, interest income %, and prohibited revenue that caused the failure. Know before you sell or hold.

Free for 7 days. Cancel anytime.

Card needed, nothing charged today

AI Compliance Insight

PRO

Institutional-grade Shariah analysis

Card needed, nothing charged today

See why TRDA is rated Not Halal with institutional-grade analysis

Compliance History

Not Halal, unchanged since May 2026.

No status changes recorded since we began tracking.

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: EDGAR
Free · No credit card required

Know the day TRDA's verdict changes

A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.

8,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Entrada Therapeutics, Inc. (TRDA) halal to invest in?
Entrada Therapeutics, Inc. (TRDA) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.
Why did Entrada Therapeutics, Inc. get a F compliance rating?
Entrada Therapeutics, Inc. (TRDA) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 28.4% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Entrada Therapeutics, Inc.'s Shariah verdict?
Entrada Therapeutics, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Entrada Therapeutics, Inc. re-screened for Shariah compliance?
Entrada Therapeutics, Inc. (TRDA) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Oct 14, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.